Objective To investigate the effects of dexmedetomidine on hemodynamics and tra-cheal intubation facility in general anesthetized patients.Methods Forty gynecological patients of se-lective operation under general anesthesia were randomly arranged into 2 groups:group D and group C.With high flow mask oxygen inhalation(5 L/min),dexmedetomidine was intravenously pumped in-to the patients in group D at 0.6μg/kg in 10 minutes while in group C saline were given instead.Both groups were then proceeded with rapid sequence induction (RSI)immediately.The values of MAP, HR,PaO2 and PaCO2 were recorded every minute from pumping start till 15 minutes,the bucking, intubation time and glottis exposure were evaluated as well.Results No significant differences were found in intubation time or glottis exposure between these two groups.After tracheal intubation group D showed higher MAP value than group C at 14,15 minutes,and a lower HR value (P <0.05).Even no significant differences were found in values of SpO2 and PaO2 ,the group D showed less bucking than the group C (P<0.05).Conclusion Dexmedetomidine administration at 0.6μg/kg in RSI can diminish the variation in hemodynamics and facilitate the tracheal intubation by less buc-king,but no affect the oxygen reserve.

Chronic osteomyelitis (COM) is an infectious disease caused by methicillin-resistant Staphylococcus aureus (MRSA),the main characteristics of COM including local dead bone formation,soft tissue infection,and repeatedly attacks.As a sensitive antibiotic,vancomycin plays an important role in the therapy of COM caused by MRSA.Currently,drug treatment is divided into systemic and topical,systemic medication is given priority to intravenous drug delivery;local drug application including local delivery device and local antibiotics lavage and regional arterial perfusion.In practice,its validity depends on whether free drug concentration of vancomycin has riched the effective concentration in the organization.Nevertheless,low concentration lead to treatment failure and even induce drug-resistance bacteria,meanwhile high concentration may cause acute renal failure.So when using vancomycin for the treatment of chronic osteomyelitis,both drug resistance and renal toxicity is as the same important as the effectiveness.Systemic administration is a targeting weak way and has many complications;topical medicate effect on the lesion can be targeted,it would be an effective way in the future treatment of COM.Different methods of delivering vancomycin have great influence on local drug concentration,which makes it become the most important factor on local drug concentration of COM.

Chronic osteomyelitis (COM) is an infectious disease caused by methicillin-resistant Staphylococcus aureus (MRSA),the main characteristics of COM including local dead bone formation,soft tissue infection,and repeatedly attacks.As a sensitive antibiotic,vancomycin plays an important role in the therapy of COM caused by MRSA.Currently,drug treatment is divided into systemic and topical,systemic medication is given priority to intravenous drug delivery;local drug application including local delivery device and local antibiotics lavage and regional arterial perfusion.In practice,its validity depends on whether free drug concentration of vancomycin has riched the effective concentration in the organization.Nevertheless,low concentration lead to treatment failure and even induce drug-resistance bacteria,meanwhile high concentration may cause acute renal failure.So when using vancomycin for the treatment of chronic osteomyelitis,both drug resistance and renal toxicity is as the same important as the effectiveness.Systemic administration is a targeting weak way and has many complications;topical medicate effect on the lesion can be targeted,it would be an effective way in the future treatment of COM.Different methods of delivering vancomycin have great influence on local drug concentration,which makes it become the most important factor on local drug concentration of COM.

Blood-brain barrier (BBB) damage after ischemia significantly influences stroke outcome. Compound LFHP-1c was previously discovered with neuroprotective role in stroke model, but its mechanism of action on protection of BBB disruption after stroke remains unknown. Here, we show that LFHP-1c, as a direct PGAM5 inhibitor, prevented BBB disruption after transient middle cerebral artery occlusion (tMCAO) in rats. Mechanistically, LFHP-1c binding with endothelial PGAM5 not only inhibited the PGAM5 phosphatase activity, but also reduced the interaction of PGAM5 with NRF2, which facilitated nuclear translocation of NRF2 to prevent BBB disruption from ischemia. Furthermore, LFHP-1c administration by targeting PGAM5 shows a trend toward reduced infarct volume, brain edema and neurological deficits in nonhuman primate